MONIQUE THAMMAVONG: Open Payments
NPI 1275932253 · VAN BUREN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 33 payments from 11 companies in 2025. Trend: 2023 $775 · 2024 $764 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $220 |
| ABBVIE INC. | 12 | $137 |
| Stryker Corporation | 1 | $121 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $87 |
| Exact Sciences Corporation | 2 | $37 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $36 |
| Astellas Pharma US Inc | 1 | $23 |
| Novartis Pharmaceuticals Corporation | 1 | $23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
Products named: VRAYLAR, AIRSUPRA, FLOWTRIEVER, BREZTRI, JOURNAVX, CAPLYTA, Veozah, LEQVIO.
Industry payments across AR — which companies pay providers there.
